Kuznicki Law PLLC notifies investors that a class action has commenced in the United States District Court for the Southern District of New York on behalf of shareholders of DexCom, Inc. who purchased shares between July 26, 2026 and September 17, 2025.
DexCom and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On September 18, 2025, Hunterbrook published a report addressing the Company, entitled “Dexcom’s Fatal Flaws,” revealing that issues and health risks posed by the Company’s adulterated G7 devices were more severe and widespread than previously disclosed, citing FDA documents it had procured via a Freedom of Information Act request, as well as various comments from doctors, patients and their families, and former DexCom employees. Specifically, the Hunterbrook report found that “G7 users have been hospitalized and died” following inaccurate glucose readings, linking these deadly incidents to adulterated G7 devices and the Company’s willingness to cut corners to meet margins.
On this news, the price of DexCom’s shares fell $8.99 per share, or 11.76%, over the following two trading sessions, to close at $67.45 per share on September 19, 2025.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until December 26, 2025 to request that the court appoint them lead plaintiff.